HK1220125A1 - 拉喹莫德的透皮配方 - Google Patents

拉喹莫德的透皮配方 Download PDF

Info

Publication number
HK1220125A1
HK1220125A1 HK16108223.4A HK16108223A HK1220125A1 HK 1220125 A1 HK1220125 A1 HK 1220125A1 HK 16108223 A HK16108223 A HK 16108223A HK 1220125 A1 HK1220125 A1 HK 1220125A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
laquinimod
optionally
transdermal patch
provides
Prior art date
Application number
HK16108223.4A
Other languages
English (en)
Chinese (zh)
Inventor
Stefan Ralph
Mika Hans-Juergen
Pries Tanja
Schenk Dirk
Prohl Sabine
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of HK1220125A1 publication Critical patent/HK1220125A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16108223.4A 2013-03-14 2014-03-13 拉喹莫德的透皮配方 HK1220125A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361781585P 2013-03-14 2013-03-14
US61/781,585 2013-03-14
PCT/US2014/026807 WO2014152009A1 (en) 2013-03-14 2014-03-13 Transdermal formulations of laquinimod

Publications (1)

Publication Number Publication Date
HK1220125A1 true HK1220125A1 (zh) 2017-04-28

Family

ID=50729775

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16108223.4A HK1220125A1 (zh) 2013-03-14 2014-03-13 拉喹莫德的透皮配方

Country Status (8)

Country Link
US (1) US20160038435A1 (enExample)
EP (1) EP2968203A1 (enExample)
JP (1) JP2016513665A (enExample)
CA (1) CA2900977A1 (enExample)
HK (1) HK1220125A1 (enExample)
IL (1) IL240557A0 (enExample)
MX (1) MX2015010967A (enExample)
WO (1) WO2014152009A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
WO2015138887A1 (en) * 2014-03-14 2015-09-17 Teva Pharmaceutical Industries Ltd. Transmucosal delivery of laquinimod by oral patches
CN112656778A (zh) * 2020-12-28 2021-04-16 广东红珊瑚药业有限公司 一种压敏胶基质以及一种贴剂

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
RS53666B1 (sr) 2005-10-19 2015-04-30 Teva Pharmaceutical Industries Ltd Kristali lakvinimod natrijuma i proces za njihovo dobijanje
UA96449C2 (en) 2006-06-12 2011-11-10 Тева Фармасьютикл Индастриз, Лтд. Stable laquinimod preparations
SI2234485T1 (sl) 2007-12-20 2014-03-31 Teva Pharmaceutical Industries Ltd. Stabilni lakvinimodni pripravki
BRPI0913518A2 (pt) 2008-09-03 2016-07-26 Teva Pharma composto, composição farmacêutica, e, método de tratamento de um distúrbio mediado por função imune
WO2010147665A1 (en) 2009-06-19 2010-12-23 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod
CA2769623A1 (en) 2009-07-30 2011-02-03 Teva Pharmaceutical Industries Ltd. Treatment of crohn's disease with laquinimod
HUE029983T2 (en) 2009-08-10 2017-04-28 Teva Pharma Treatment of BDNF-related diseases with laquinimod
DE102010026879A1 (de) * 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
CN102781240A (zh) 2010-03-03 2012-11-14 泰华制药工业有限公司 用拉喹莫德和甲氨蝶呤的组合治疗类风湿性关节炎
BR112012022064A2 (pt) 2010-03-03 2015-09-08 Teva Pharma tratamento de artrite lúpica usando laquinimod
BR112012021905A2 (pt) 2010-03-03 2015-09-29 Teva Pharma tratamento de nefrite lúpica usando laquinimod
US8252993B1 (en) 2010-05-25 2012-08-28 Pioneer Hi-Bred International, Inc. Inbred maize variety PH18FN
MX2013000333A (es) 2010-07-09 2013-02-26 Teva Pharma N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma.
BR112013000607A2 (pt) 2010-07-09 2016-06-28 Teva Pharma 5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-di-hidroquinolina-3-carboxamida, os sais e suas utilizações
KR20130124518A (ko) 2010-12-07 2013-11-14 테바 파마슈티컬 인더스트리즈 리미티드 다발경화증 환자의 피로를 감소시키고, 기능 상태를 개선시키고, 삶의 질을 개선시키기 위한 라퀴니모드의 용도

Also Published As

Publication number Publication date
MX2015010967A (es) 2015-10-26
JP2016513665A (ja) 2016-05-16
US20160038435A1 (en) 2016-02-11
WO2014152009A1 (en) 2014-09-25
CA2900977A1 (en) 2014-09-25
IL240557A0 (en) 2015-10-29
EP2968203A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
PH12015502550A1 (en) Transdermal delivery system
WO2015023649A3 (en) Peptides for enhancing transdermal delivery
MX2022008277A (es) Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas.
MX366560B (es) Parche adhesivo con composicion antimicrobiana.
MX2016008138A (es) Sistema para el suministro transdermico de ingredientes activos.
MX2012002727A (es) Sistema terapeutico transdermico para administrar fentanilo o un analogo del mismo.
NZ611920A (en) Percutaneous absorption preparation containing rivastigmine
MY183873A (en) Transdermal therapeutic system for application of an agent
WO2011076621A3 (de) Transdermales therapeutisches system zur verabreichung von rivastigmin oder dessen derivaten
MX382132B (es) Sistema terapeutico transdermico que contiene asenapina y polisiloxano o poliisobutileno
NO20092998L (no) Flytende formuleringer, som danner dermal film, for frigjoring av legemidler til huden
PH12015502280A1 (en) Transdermal delivery system comprising donepezil or its salt
HK1215677A1 (zh) 经皮递送系统
MX2018009575A (es) Sistema y metodo para conservar y suministrar un gas terapeutico a una herida.
HK1220125A1 (zh) 拉喹莫德的透皮配方
EA201300648A1 (ru) Трансдермальная терапевтическая система (tts), содержащая ротиготин
SG10201908690WA (en) Novel method of use and compositions
UY33663A (es) Derivados amínicos para el tratamiento de trastornos proliferativos de la piel
WO2012111996A3 (ko) 갈란타민 또는 그의 염을 함유하는 경피흡수제제
MY184693A (en) Bilayer hydrocolloid films containing therapeutic agents
BR112014018426A8 (pt) Composição e dispositivo para administração transdérmica, e, método para administrar uma progestina
WO2013010137A3 (en) A composition, device and method for delayed and sustained release of brain energy molecules
EP2412390A3 (en) Adhesive patch and patch preparation
MX2017005046A (es) Metodo y articulos para inhibir las contracciones vesicales.
MY162768A (en) Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)